You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address